Management of Pediatric Nephrotic Syndrome
For initial treatment of pediatric nephrotic syndrome, give oral prednisone/prednisolone for either 8 weeks (4 weeks daily followed by 4 weeks alternate-day) or 12 weeks (6 weeks daily followed by 6 weeks alternate-day), with the choice based on balancing efficacy against steroid toxicity risk 1.
Initial Episode Treatment
The cornerstone of management is oral glucocorticoid therapy. The KDIGO 2025 guideline provides two acceptable regimens 1:
- 8-week protocol: 4 weeks daily prednisone/prednisolone, then 4 weeks alternate-day
- 12-week protocol: 6 weeks daily prednisone/prednisolone, then 6 weeks alternate-day
Both regimens have equivalent evidence strength (1B recommendation). The longer 12-week course may reduce early relapse risk but increases steroid exposure. Most children (approximately 80-90%) will respond to initial steroid therapy, defining them as steroid-sensitive nephrotic syndrome (SSNS) 2.
Critical pitfall: Recent evidence shows that longer steroid regimens beyond these recommendations do not improve outcomes or reduce relapse rates 3. Avoid extending therapy beyond 12 weeks in the initial episode.
Management of Relapses
Infection-Associated Relapses
Do not routinely give daily glucocorticoids during upper respiratory tract infections to prevent relapses 1. This represents a significant practice change based on the PREDNOS2 trial, which demonstrated no benefit of prophylactic steroids during infections. The previous practice of giving extra steroid doses at infection onset is no longer recommended for routine use.
Relapse Treatment Strategy
For children experiencing relapses without glucocorticoid toxicity:
- Use the same glucocorticoid regimen as the initial episode
- Consider low-dose alternate-day prednisone/prednisolone for relapse prevention in frequently relapsing nephrotic syndrome (FR-NS) 1
For children showing signs of glucocorticoid toxicity:
- Implement shorter steroid tapers
- Move quickly to steroid-sparing agents 1
Steroid-Sparing Therapy
For children with frequently relapsing nephrotic syndrome who develop serious glucocorticoid-related adverse effects, and for all children with steroid-dependent nephrotic syndrome, prescribe glucocorticoid-sparing agents rather than continuing glucocorticoids alone 1.
Agent Selection Algorithm
The KDIGO 2025 guideline eliminates the previous first-line/alternative agent hierarchy. Instead, choose based on disease pattern 1:
For Frequently Relapsing Nephrotic Syndrome (FR-NS):
- Preferred agents: Oral cyclophosphamide or levamisole
- These work well when relapses occur but steroid dependence hasn't developed
For Steroid-Dependent Nephrotic Syndrome (SD-NS):
- Preferred agents: Mycophenolate mofetil, rituximab, calcineurin inhibitors (cyclosporine/tacrolimus), or oral cyclophosphamide
- Rituximab dosing ranges from 1-4 doses in current trials, though specific dosing recommendations remain insufficient 1
- In complicated FR-NS or SD-NS cases, mycophenolate mofetil after rituximab decreases treatment failure risk 1
Implementation Details
Before starting steroid-sparing agents:
- Achieve remission with glucocorticoids first
- Continue glucocorticoids for 2 weeks after initiating the steroid-sparing agent 1
This overlap prevents breakthrough relapses during the lag time before the steroid-sparing agent becomes effective.
Steroid-Resistant Nephrotic Syndrome (SRNS)
Use cyclosporine or tacrolimus as initial second-line therapy for children with SRNS 1. This remains the standard approach with calcineurin inhibitors as the backbone of SRNS management.
For calcineurin inhibitor-resistant SRNS:
- Rituximab achieves remission in approximately 30% of children 1
- Mycophenolate mofetil has very limited evidence in this population 1
Critical consideration: Up to one-third of SRNS cases have a monogenic origin 2. These patients often progress to multidrug-resistant disease and kidney failure, with potential post-transplant recurrence. Genetic testing should inform treatment decisions, particularly regarding the aggressiveness of immunosuppression.
Age-Specific Considerations
Children aged 2-6 years represent the highest-risk group for developing FR-NS, with 70-100% of FR-NS cases in various cohorts falling within this age range 3. This age group requires particularly vigilant monitoring and earlier consideration of steroid-sparing strategies to minimize cumulative steroid exposure during critical developmental years.
Monitoring and Complications
Close disease monitoring is essential but faces practical barriers. The lack of insurance coverage for urine dipsticks in the United States significantly impairs optimal disease management 4. Advocate for coverage or provide alternative monitoring strategies.
Acute complications requiring immediate attention include:
- Hypovolemia (despite edema)
- Acute kidney injury
- Infections (due to immunosuppression and urinary immunoglobulin loss)
- Thrombosis (from urinary antithrombin loss) 2, 5
Long-term complications from disease and treatment:
- Metabolic bone disease
- Micronutrient deficiencies
- Hyperlipidemia
- Growth impairment 6
Supportive Management
Edema management combines:
- Fluid and sodium restriction
- Diuretics
- Albumin infusions when indicated 6
Avoid aggressive diuresis without albumin in severely hypoalbuminemic patients, as this precipitates hypovolemic complications despite total body fluid overload.